{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:45:30Z","timestamp":1747183530241,"version":"3.40.5"},"reference-count":111,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Non\u2010Hodgkin lymphomas (<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>s) are a heterogeneous group of malignancies. Most <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>s in children, adolescent and young adult patients are aggressive lymphomas that are generally treated with multi\u2010agent chemotherapy or immunochemotherapy regimens. While overall survival is high, the treatment can lead to a high rate of acute and long\u2010term toxicity. However, in the rarer instance of relapsed or refractory disease, outcomes are dismal. Novel therapeutic approaches to the treatment of both T\u2010cell and B\u2010cell <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>s are critical to improve outcomes while also minimising the associated toxicity of current treatment regimes. Potential therapeutic approaches in development include humoral and cellular immunotherapies, small molecule inhibitors of relevant signalling pathways and epigenetic modifying agents. In this review, we will highlight the current state of development of agents of interest with a focus on agents relevant to childhood, adolescent and young adult <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.15783","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T01:29:47Z","timestamp":1548898187000},"page":"1111-1124","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non\u2010Hodgkin lymphoma"],"prefix":"10.1111","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5263-9509","authenticated-orcid":false,"given":"Matthew J.","family":"Barth","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology University at Buffalo Roswell Park Comprehensive Cancer Center Buffalo NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Minard\u2010Colin","sequence":"additional","affiliation":[{"name":"Department of Paediatric and Adolescent Oncology Gustave Roussy Villejuif France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10396"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00021-1"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1164140"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13764"},{"key":"e_1_2_8_7_1","first-page":"47","article-title":"Synergistically enhanced in\u2010vitro cytotoxicity and overall survival in NSG xenografts against Burkitt lymphoma (BL) and primary mediastinal large B cell lymphoma (PMBL) by polatuzumab vedotin (hu\u2010 anti\u2010CD79b\u2010vc\u2010MMAE, PV) alone or in\u2010combination with obinutuzumab","volume":"182","author":"Awasthi A.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_8_1","first-page":"67","article-title":"Blinatumomab significantly enhanced cytotoxicity and T\u2010cell cytokine secretion against Burkitt lymphoma (BL) and primary mediastinal B\u2010cell lymphoma (PMBL)","volume":"182","author":"Awasthi A.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-683516"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08966.x"},{"key":"e_1_2_8_11_1","first-page":"48","article-title":"Phase 2 trial of obinutuzumab, a humanized, glycoengineered monoclonal CD20 antibody, in combination with ifosfamide, carboplatin and etoposide for relapsed\/refractory mature B\u2010cell Non\u2010Hodgkin lymphoma","volume":"182","author":"Barth M.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1256481"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25072"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0222-5"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-474148"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08669.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-794214"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30030-9"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1487"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08006.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.7661"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2764-1"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.11.003"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-100115"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0855"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1769"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0114"},{"key":"e_1_2_8_29_1","first-page":"46","article-title":"2B8T2M, a novel fusion of ALT\u2010803, an IL\u201015 superagonist, with 4 single\u2010chains of anti\u2010CD20 Antibody significantly enhanced expanded natural killer cells cytotoxicity against rituximab sensitive and resistant Burkitt lymphoma (BL)","volume":"182","author":"Chu Y.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12537"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08638"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-349662"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx289"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.10500"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2014.2525"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.10.005"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236471"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1511045"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.10005"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-437624"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1586"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.255"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13040"},{"key":"e_1_2_8_45_1","first-page":"11","article-title":"Reduced burden of oncologic therapy in children, adolescents and young adults with good risk (GR) CD20\u00a0+\u00a0 mature B\u2010cell lymphoma","volume":"182","author":"Goldman S.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21753"},{"key":"e_1_2_8_49_1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2018-99-113534","article-title":"Clinical responses to CAR.CD30\u2010T cells in patients with CD30+ lymphomas relapsed after multiple treatments including Brentuximab Vedotin","volume":"132","author":"Grover N.S.","year":"2018","journal-title":"Blood"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1535-z"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08123.x"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.7326\/L16-0037"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5272"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0135-z"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6004"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0822"},{"key":"e_1_2_8_57_1","first-page":"2951","article-title":"Omipalisib (GSK458), a dual pan\u2010PI3K\/mTOR inhibitor, exhibits in\u00a0vitro and in\u00a0vivo activity in chemotherapy\u2010sensitive and \u2013resistant models of Burkitt lymphoma","volume":"182","author":"Ippolito T.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30145-1"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-016-0428-y"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1703966114"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14877"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2966"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139162"},{"key":"e_1_2_8_64_1","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1182\/blood.V126.23.5117.5117","article-title":"Ibrutinib significantly prolonged survival in a Human Burkitt Lymphoma (BL) xenograft NSG mouse model: ibrutinib may be a potential adjuvant agent in the treatment of BL","volume":"126","author":"Lee S.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"e_1_2_8_66_1","first-page":"37","article-title":"Ruxolitinib significantly enhances in\u00a0vitro apoptosis in Hodgkin Lymphoma (HL) and primary mediastinal B\u2010cell lymphoma (PMBL) and survival in a lymphoma xenograft murine mouse: an AYA therapeutic opportunity","volume":"182","author":"Levine S.R.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2015-2673"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30153-4"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2468"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-597914"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810958105"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11606"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108190108"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25990"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.205"},{"key":"e_1_2_8_76_1","doi-asserted-by":"crossref","first-page":"10507","DOI":"10.1200\/JCO.2016.34.15_suppl.10507","article-title":"Results of the randomized Intergroup trial Inter\u2010B\u2010NHL Ritux 2010 for children and adolescents with high\u2010risk B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL) and mature acute leukemia (B\u2010AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen","volume":"34","author":"Minard\u2010Colin V.","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10351"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9585"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1247956"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4830"},{"key":"e_1_2_8_81_1","first-page":"44","article-title":"Therapy and outcome of children and adolescents with progressive or relapsed lymphoblastic lymphoma: updated NHL\u2010BFM experience","volume":"182","author":"Muller S.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_82_1","first-page":"37","article-title":"Ibrutinib significantly inhibited bruton's tyrosine kinase (BTK) phosphorylation, in\u2010vitro proliferation and enhanced overall survival in a preclinical burkitt lymphoma (BL) model","volume":"182","author":"Nayyar G.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25751"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04687"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0898-6568(01)00271-6"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12683"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305656110"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780049"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26902"},{"key":"e_1_2_8_91_1","first-page":"2957","article-title":"Early response data for pediatric patients with Non\u2010Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T\u2010cells","volume":"182","author":"Rivers J.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.06.012"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1841"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11378"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_6"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.06.002"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595934"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12531"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2345"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10040114"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13033"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0039"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13958"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3402"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70261-8"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.226"},{"key":"e_1_2_8_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.57"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70311-0"},{"key":"e_1_2_8_110_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169656"},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.223"},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758383"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15783","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15783","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15783","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T21:25:14Z","timestamp":1694381114000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":111,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/bjh.15783"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15783","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"assertion":[{"value":"2018-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}